Prenetics Reports Q3 2026 Revenue Beat Driven by IM8 Brand Growth
Prenetics (PRE) reported third-quarter revenue of $64.1 million, surpassing its previous guidance range. The growth was primarily driven by the IM8 wellness brand, which generated $62.9 million in revenue—a 39.8% sequential increase. While total revenue exceeded expectations, the company revised its second-half Adjusted EBITDA loss guidance to a range of $30 million to $35 million, up from previous estimates, as it prioritizes aggressive customer acquisition and marketing spend. The company is leveraging a $1 billion growth financing facility from General Catalyst to fund much of its marketing efforts. Management highlighted strong unit economics, including a declining customer acquisition cost and high cohort returns. Looking ahead, Prenetics aims to expand into the retail market and enter China by the end of 2027, while targeting long-term Adjusted EBITDA margins of 15% to 25%.

Tickers: $PRE
Topics: Customer Acquisition EBITDA Loss Financial Performance Revenue Growth